Approval · Notice of Compliance 10674 · 2009
LOVASTATIN: Notice of Compliance 10674
Issued October 16, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10674
- Date
- October 16, 2009
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Lipid metabolism regulator
- Canadian reference product
- MEVACOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVASTATIN | 02333848 | — |
| LOVASTATIN | 02333821 | — |
Medicinal ingredients
- LOVASTATIN 40 MG per TAB
- LOVASTATIN 20 MG per TAB